A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma [FL], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

This was an open-label, single-arm safety and efficacy study of duvelisib administered orally to participants who had been diagnosed with iNHL whose disease was refractory to rituximab and to either chemotherapy or RIT.

Approximately 120 participants received 25 milligrams of duvelisib twice daily over the course of 28-day treatment cycles for up to 13 cycles.

After completing 13 treatment cycles of duvelisib, participants continued to receive additional cycles of duvelisib until disease progression or unacceptable toxicity. However, to receive additional cycles of duvelisib beyond 13 cycles, participants must have had evidence of response (complete response [CR] or partial response [PR]) or stable disease according to the International Working Group criteria by the end of Cycle 13.

Inclusion Criteria:

• Participants who had been diagnosed with iNHL that had progressed.
• Participants must have exhibited lack of CR or progressive disease (PR) or progression within 6 months after the last dose of a chemotherapy induction regimen or RIT.
• Participants must have had rituximab-refractory disease, defined as lack of CR or PR or PD within 6 months of last dose.
• Measurable disease with a lymph node or tumor mass ≥1.5 centimeters in at least one dimension by computed tomography (CT), positron emission tomography/CT or magnetic resonance imaging.
• Adequate renal and hepatic function.

Exclusion Criteria:

• Candidate for potentially curative therapies in the opinion of the investigator.
• Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor.
• Prior history of allogeneic hematopoietic stem cell transplant.
• Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.
• Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.
• Symptomatic central nervous system NHL.
• Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.
• Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies.
• History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.